Overview

Pharmacokinetic, Pharmacodynamic Profiles and Safety After Oral Administration of Ivabradine in Male Healthy Korean Volunteers

Status:
Completed

Trial end date:
2007-11-01

Target enrollment:

Participant gender:

Summary

1. To assess the pharmacokinetic profile of ivabradine (S 16257) and its main active metabolite S 18982 in Korean healthy volunteers after oral administration of ivabradine at the doses of 2.5, 5, 10mg and after repeated oral administrations of ivabradine for 4.5 days at the same doses twice daily versus placebo and to use the study results for bridging with Caucasian data. 2. The pharmacodynamic profile of ivabradine versus placebo by measuring its effects on heart rate after single and then after repeated administrations. 3. Clinical safety of ivabradine versus placebo.

Phase:

Phase 1

Details

Lead Sponsor:

Asan Medical Center

Collaborator:

Institut de Recherches Internationales Servier